U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06959511) titled 'Neoadjuvant Treatment With Zanzalintinib for Advanced Thyroid Cancer' on April 28.
Brief Summary: To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
Study Start Date: Oct. 22, 2025
Study Type: INTERVENTIONAL
Condition:
Neoadjuvant Treatment
Thyroid Cancer
Intervention:
DRUG: Zanzalintinib
Given by po
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Disclaimer: Curated by HT Syndication....